Evaluation of the immune response against COVID-19 in pediatric Cancer patients after vaccinatio

Recruiting

• Conditions: eed for vaccination against COVID-19; C91; C92; Lymphoid leukaemia; Myeloid leukaemia

• Registration Number: DRKS00025254
• Lead Sponsor: Pädiatrische Hämatologie und OnkologieKlinik für Kinder- und JugendmedizinJohann Wolfgang Goethe Universität

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2021-05-26
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

Patients treated for malignoima (both during intensive chemotherapy and in maintenance therapy) up to 3 months after cessation of chemotherapy
- Age 16-18 years (youngert once the vaccine will be approved for this age Group)
- No contraindication for SARS-CoV-2 vaccination
- Written informed consent Patient and caregiver

Exclusion Criteria

- known inborn immunodeficiency
- Prior infection with SARS-CoV-2

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Primary endpoints<br>Specific antibodies against the spike-Protein and/or nucleocapsid of SARS-CoV-2<br><br>Neutralisation test (neutralising antibodies)<br><br>Specific T cells and specific Memory B cells against SARS-CoV-2

Secondary Outcome Measures

Name	Time	Method
Secondary endpoint<br>Infection or disease with SARS-CoV-2, defined as positive PCR test during study period